IL-5 CAR-T therapy for eosinophilic leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This phase 1 trial tests a new treatment called IL-5 CAR-T for patients with eosinophilic leukemia that has not responded to or has returned after standard therapy. It uses your own immune cells that are modified to target and kill cancer cells that have a specific marker called CD125.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Have eosinophilic leukemia that has not improved with standard treatments or has come back within 6 months
- Have at least 50% of your leukemia cells showing a specific target (CD125)
- Have adequate organ function (liver, heart, and oxygen levels) as determined by blood tests and scans
- Have an estimated life expectancy of more than 3 months and a good performance status (able to care for yourself)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, engineered to find and attack cancer cells that have a protein called CD5. It is for people with a type of T-cell lymphoma that has come back or not responded to other treatments.
This trial tests a new type of immune therapy—called CD5-targeting CAR T-cells—for people with a hard-to-treat form of T-cell acute lymphoblastic leukemia. It aims to see if these specially designed cells can find and destroy leukemia cells with the CD5 marker.
This early-phase study tests a customized immune-cell therapy (CAR-T) made from your own T cells to treat acute myeloid leukemia (AML) that has the marker CD123. It may help shrink the leukemia and improve long-term control, but the treatment is still being tested for safety and early effectiveness.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are reprogrammed to find and destroy T-cell leukemia or lymphoma cells that have the CD5 protein. It may be an option if your cancer has come back or hasn't responded to other treatments.
This trial tests a new immune cell therapy (CAR T-cells) that targets CD5 found on certain T-cell cancers. It may be an option for people whose cancer has not responded to other treatments.
Hear when a new Hematologic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.